Chinese General Practice ›› 2022, Vol. 25 ›› Issue (17): 2126-2134.DOI: 10.12114/j.issn.1007-9572.2021.02.007
Special Issue: 社区卫生服务最新研究合辑; 消化系统疾病最新文章合辑
• Article • Previous Articles Next Articles
Received:
2021-05-23
Revised:
2021-10-27
Published:
2022-04-22
Online:
2022-04-22
Contact:
Jilin MA
About author:
通讯作者:
马纪林
作者简介:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.007
组别 | 例数 | 女性〔n(%)〕 | 年龄( | BMI(kg/m2) | 腰围( | 臀围( | 腰臀比( | 收缩压( | 舒张压( | 空腹血糖( | 总胆固醇( | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
健康对照组 | 1 075 | 737(68.56) | 59.5±9.2 | 22.2±2.6 | 74.5±7.6 | 88.5±5.1 | 0.84±0.06 | 118±11 | 77±7 | 5.3±0.5 | 4.70±0.70 | |
对照组 | 1 948 | 1 083(55.60)a | 64.7±9.0a | 23.4±2.6a | 79.1±7.8a | 90.6±5.4 | 0.87±0.06a | 140±17a | 86±10a | 6.0±1.6a | 4.94±1.04 | |
NAFLD组 | 1 248 | 1 045(83.73)ab | 63.2±7.8ab | 26.1±3.0ab | 83.7±7.6ab | 94.0±5.8 | 0.89±0.05ab | 139±17a | 85±9a | 6.0±1.4a | 5.21±1.05 | |
MAFLD组 | 1 456 | 995(68.34)bc | 64.7±8.3ac | 27.9±3.0abc | 90.2±7.8abc | 97.3±6.3 | 0.93±0.05abc | 142±18abc | 86±10a | 7.4±2.5abc | 5.18±1.13 | |
检验统计量值 | 96.707 | 98.774 | 1 137.694 | 1 005.658 | 631.238 | 573.261 | 557.742 | 255.693 | 357.480 | 65.384 | ||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
组别 | 三酰甘油( | LDL-C( | HLD-C( | 总胆红素( | 血尿酸( | ALT( | AST( | ALT/AST( | GGT〔M(QR),U/L〕 | eGFR〔 | 白细胞计数( | |
健康对照组 | 1.10±0.40 | 2.96±0.63 | 1.60±0.34 | 12.33±6.10 | 281.73±68.59 | 16±13 | 21±8 | 0.74±0.25 | 14.95(22.56) | 90.91±13.05 | 5.5±1.3 | |
对照组 | 1.44±0.96a | 3.18±0.96 | 1.48±0.38a | 12.47±5.38 | 310.08±81.23a | 17±11a | 21±8 | 0.79±0.27a | 18.67(28.44) | 85.60±14.81a | 5.9±1.5a | |
NAFLD组 | 1.76±0.92ab | 3.46±0.96 | 1.38±0.28ab | 12.02±5.04 | 327.10±76.86ab | 26±19ab | 24±12ab | 1.03±0.34ab | 24.55(37.01) | 88.62±12.45ab | 6.1±1.4ab | |
MAFLD组 | 2.66±1.72abc | 3.29±1.03 | 1.17±0.27abc | 11.99±4.78 | 351.50±84.15abc | 31±23abc | 26±14abc | 1.14±0.36abc | 30.40(46.71) | 86.25±14.62ac | 6.6±1.6abc | |
检验统计量值 | 479.960 | 59.596 | 411.073 | 3.136 | 175.232 | 268.532 | 83.674 | 541.209 | 78.484e | 39.971 | 141.461 | |
P值 | <0.001 | <0.001 | <0.001 | 0.024 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 中性粒细胞计数( | 单核细胞计数( | 淋巴细胞计数( | 血小板计数( | NLR( | PLR( | LMR( | MHR( | ANI〔M(QR)〕 | LAP( | AIP( | |
健康对照组 | 3.2±1.1 | 0.3±0.1 | 1.8±0.5 | 220.1±59.0 | 0.23±0.10 | 130.06±44.65 | 1.90±0.94 | 0.20±0.09 | 130.06±44.65 | 16.24±10.96 | -0.18±0.21 | |
对照组 | 3.5±1.2a | 0.4±0.2a | 1.9±0.6a | 222.7±62.9 | 0.29±0.15a | 125.62±46.16a | 1.99±1.04a | 0.22±0.09a | 125.62±46.16a | 26.75±21.82a | -0.05±0.28a | |
NAFLD组 | 3.5±1.1a | 0.4±0.1ab | 2.1±0.6ab | 236.5±58.7ab | 0.29±0.11a | 120.35±40.29ab | 1.79±0.70ab | 0.20±0.07ab | 120.35±40.29ab | 41.70±21.28ab | 0.07±0.23ab | |
MAFLD组 | 3.8±1.1abc | 0.4±0.1abc | 2.2±0.7abc | 234.8±64.3ab | 0.39±0.16abc | 113.80±40.36abc | 1.86±0.76bc | 0.21±0.08bc | 113.80±40.36abc | 77.62±49.89abc | 0.31±0.27abc | |
检验统计量值 | 72.693 | 84.465 | 119.124 | 24.379 | 298.825 | 35.014 | 13.422 | 29.055 | 35.014e | 1 094.515 | 914.337 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 腰围分类〔n(%)〕 | BMI分类〔n(%)〕 | 高血压〔n(%)〕 | 血脂异常〔n(%)〕 | ||||||||
≥90 cm(男)或≥85 cm(女) | <90 cm(男)或<85 cm(女) | 正常 | 超重 | 肥胖 | 无 | 有 | 无 | 高胆固醇血症 | 高三酰甘油血症 | 混合性高脂血症 | 低高密度脂蛋白血症 | |
健康对照组 | 58(5.40) | 1 017(94.60) | 741(68.93) | 220(20.47) | 114(10.60) | 1 075(100.00) | 0 | 1 075(100.00) | 0 | 0 | 0 | 0 |
对照组 | 264(13.55) | 1 684(86.45) | 1 087(55.80) | 690(35.42) | 171(8.78) | 146(7.49) | 1 802(92.51) | 1 475(75.72) | 173(8.88) | 172(8.83) | 35(1.80) | 93(4.77) |
NAFLD组 | 380(30.45) | 868(69.55) | 267(21.39) | 666(53.37) | 315(25.24) | 211(16.91) | 1 037(83.09) | 850(68.11) | 131(10.50) | 178(14.26) | 66(5.29) | 23(1.84) |
MAFLD组 | 1 104(75.82) | 352(24.18) | 122(8.38) | 653(44.85) | 681(46.77) | 153(10.51) | 1 303(89.49) | 545(37.43) | 109(7.49) | 524(35.99) | 136(9.34) | 142(9.75) |
检验统计量值 | 1 955.472d | 1 975.670d | 3 492.297d | 1 435.230d | ||||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 1 Comparison of general information,anthropometric indicators,blood pressure,biochemical indicators and routine blood test results between physical examinees without metabolic disorders,those with other metabolic disorders except nonalcoholic fatty liver disease and metabolic syndrome,those with nonalcoholic fatty liver disease,and those with both nonalcoholic fatty liver disease and metabolic syndrome
组别 | 例数 | 女性〔n(%)〕 | 年龄( | BMI(kg/m2) | 腰围( | 臀围( | 腰臀比( | 收缩压( | 舒张压( | 空腹血糖( | 总胆固醇( | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
健康对照组 | 1 075 | 737(68.56) | 59.5±9.2 | 22.2±2.6 | 74.5±7.6 | 88.5±5.1 | 0.84±0.06 | 118±11 | 77±7 | 5.3±0.5 | 4.70±0.70 | |
对照组 | 1 948 | 1 083(55.60)a | 64.7±9.0a | 23.4±2.6a | 79.1±7.8a | 90.6±5.4 | 0.87±0.06a | 140±17a | 86±10a | 6.0±1.6a | 4.94±1.04 | |
NAFLD组 | 1 248 | 1 045(83.73)ab | 63.2±7.8ab | 26.1±3.0ab | 83.7±7.6ab | 94.0±5.8 | 0.89±0.05ab | 139±17a | 85±9a | 6.0±1.4a | 5.21±1.05 | |
MAFLD组 | 1 456 | 995(68.34)bc | 64.7±8.3ac | 27.9±3.0abc | 90.2±7.8abc | 97.3±6.3 | 0.93±0.05abc | 142±18abc | 86±10a | 7.4±2.5abc | 5.18±1.13 | |
检验统计量值 | 96.707 | 98.774 | 1 137.694 | 1 005.658 | 631.238 | 573.261 | 557.742 | 255.693 | 357.480 | 65.384 | ||
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | ||
组别 | 三酰甘油( | LDL-C( | HLD-C( | 总胆红素( | 血尿酸( | ALT( | AST( | ALT/AST( | GGT〔M(QR),U/L〕 | eGFR〔 | 白细胞计数( | |
健康对照组 | 1.10±0.40 | 2.96±0.63 | 1.60±0.34 | 12.33±6.10 | 281.73±68.59 | 16±13 | 21±8 | 0.74±0.25 | 14.95(22.56) | 90.91±13.05 | 5.5±1.3 | |
对照组 | 1.44±0.96a | 3.18±0.96 | 1.48±0.38a | 12.47±5.38 | 310.08±81.23a | 17±11a | 21±8 | 0.79±0.27a | 18.67(28.44) | 85.60±14.81a | 5.9±1.5a | |
NAFLD组 | 1.76±0.92ab | 3.46±0.96 | 1.38±0.28ab | 12.02±5.04 | 327.10±76.86ab | 26±19ab | 24±12ab | 1.03±0.34ab | 24.55(37.01) | 88.62±12.45ab | 6.1±1.4ab | |
MAFLD组 | 2.66±1.72abc | 3.29±1.03 | 1.17±0.27abc | 11.99±4.78 | 351.50±84.15abc | 31±23abc | 26±14abc | 1.14±0.36abc | 30.40(46.71) | 86.25±14.62ac | 6.6±1.6abc | |
检验统计量值 | 479.960 | 59.596 | 411.073 | 3.136 | 175.232 | 268.532 | 83.674 | 541.209 | 78.484e | 39.971 | 141.461 | |
P值 | <0.001 | <0.001 | <0.001 | 0.024 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 中性粒细胞计数( | 单核细胞计数( | 淋巴细胞计数( | 血小板计数( | NLR( | PLR( | LMR( | MHR( | ANI〔M(QR)〕 | LAP( | AIP( | |
健康对照组 | 3.2±1.1 | 0.3±0.1 | 1.8±0.5 | 220.1±59.0 | 0.23±0.10 | 130.06±44.65 | 1.90±0.94 | 0.20±0.09 | 130.06±44.65 | 16.24±10.96 | -0.18±0.21 | |
对照组 | 3.5±1.2a | 0.4±0.2a | 1.9±0.6a | 222.7±62.9 | 0.29±0.15a | 125.62±46.16a | 1.99±1.04a | 0.22±0.09a | 125.62±46.16a | 26.75±21.82a | -0.05±0.28a | |
NAFLD组 | 3.5±1.1a | 0.4±0.1ab | 2.1±0.6ab | 236.5±58.7ab | 0.29±0.11a | 120.35±40.29ab | 1.79±0.70ab | 0.20±0.07ab | 120.35±40.29ab | 41.70±21.28ab | 0.07±0.23ab | |
MAFLD组 | 3.8±1.1abc | 0.4±0.1abc | 2.2±0.7abc | 234.8±64.3ab | 0.39±0.16abc | 113.80±40.36abc | 1.86±0.76bc | 0.21±0.08bc | 113.80±40.36abc | 77.62±49.89abc | 0.31±0.27abc | |
检验统计量值 | 72.693 | 84.465 | 119.124 | 24.379 | 298.825 | 35.014 | 13.422 | 29.055 | 35.014e | 1 094.515 | 914.337 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | |
组别 | 腰围分类〔n(%)〕 | BMI分类〔n(%)〕 | 高血压〔n(%)〕 | 血脂异常〔n(%)〕 | ||||||||
≥90 cm(男)或≥85 cm(女) | <90 cm(男)或<85 cm(女) | 正常 | 超重 | 肥胖 | 无 | 有 | 无 | 高胆固醇血症 | 高三酰甘油血症 | 混合性高脂血症 | 低高密度脂蛋白血症 | |
健康对照组 | 58(5.40) | 1 017(94.60) | 741(68.93) | 220(20.47) | 114(10.60) | 1 075(100.00) | 0 | 1 075(100.00) | 0 | 0 | 0 | 0 |
对照组 | 264(13.55) | 1 684(86.45) | 1 087(55.80) | 690(35.42) | 171(8.78) | 146(7.49) | 1 802(92.51) | 1 475(75.72) | 173(8.88) | 172(8.83) | 35(1.80) | 93(4.77) |
NAFLD组 | 380(30.45) | 868(69.55) | 267(21.39) | 666(53.37) | 315(25.24) | 211(16.91) | 1 037(83.09) | 850(68.11) | 131(10.50) | 178(14.26) | 66(5.29) | 23(1.84) |
MAFLD组 | 1 104(75.82) | 352(24.18) | 122(8.38) | 653(44.85) | 681(46.77) | 153(10.51) | 1 303(89.49) | 545(37.43) | 109(7.49) | 524(35.99) | 136(9.34) | 142(9.75) |
检验统计量值 | 1 955.472d | 1 975.670d | 3 492.297d | 1 435.230d | ||||||||
P值 | <0.001 | <0.001 | <0.001 | <0.001 |
Figure 3 ROC analysis for noninvasive indicators(including neutrophil to lymphocyte ratio,platelet to lymphocyte ratio,lymphocyte to monocyte ratio and monocyte to high-density lipoprotein cholesterol ratio)in predicting nonalcoholic fatty liver disease with metabolic syndrome in physical examinees in the community
项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | 项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | |
---|---|---|---|---|---|---|---|---|---|---|
性别(男/女) | 455/1 905 | 1 084/1 218 | 417.727a | <0.001 | PLR( | 126.88±43.84 | 114.00±41.44 | 105.961 | <0.001 | |
年龄( | 63.5±8.2 | 65.1±8.7 | 6.504 | <0.001 | LMR( | 0.18±0.06 | 0.24±0.09 | 657.565 | <0.001 | |
BMI( | 24.8±3.4 | 26.2±3.4 | 14.623 | <0.001 | ANI〔M(QR)〕 | -2.94(0.22) | -2.45(0.97) | 1.351b | 0.245 | |
腰围( | 81.0±8.5 | 86.7±8.7 | 22.600 | <0.001 | LAP( | 35.75±26.48 | 57.86±47.07 | 19.792 | <0.001 | |
臀围( | 92.1±6.2 | 95.1±6.4 | 253.068 | <0.001 | AIP( | -0.03±0.27 | 0.22±0.29 | 30.217 | <0.001 | |
腰臀比( | 0.88±0.06 | 0.91±0.06 | 20.016 | <0.001 | 腰围分类〔n(%)〕 | 169.495 | <0.001 | |||
收缩压( | 141±17 | 140±18 | 1.837 | 0.066 | ≥90 cm(男)或≥85 cm(女) | 668(28.43) | 1 080(46.92) | |||
舒张压( | 86±9 | 86±10 | 1.152 | 0.249 | <90 cm(男)或<85 cm(女) | 1 682(71.57) | 1 222(53.08) | |||
空腹血糖( | 6.2±1.7 | 6.7±2.2 | 9.522 | <0.001 | BMI分类 | 161.870a | <0.001 | |||
总胆固醇( | 5.22±1.05 | 4.94±1.09 | 8.854 | <0.001 | 正常 | 913(38.85) | 563(24.46) | |||
三酰甘油( | 1.58±0.87 | 2.24±1.63 | 17.348 | <0.001 | 超重 | 961(40.89) | 1 048(45.53) | |||
LDL-C( | 3.39±0.99 | 3.18±0.97 | 7.223 | <0.001 | 肥胖 | 476(20.26) | 691(30.01) | |||
HDL-C( | 1.53±0.34 | 1.18±0.25 | 40.574 | <0.001 | 高血压 | 5.788a | <0.001 | |||
总胆红素( | 12.16±5.22 | 12.24±5.01 | 0.234 | 0.629 | 无 | 232(9.87) | 278(12.08) | |||
血尿酸( | 304.45±73.32 | 351.25±85.38 | 20.072 | <0.001 | 有 | 2 118(90.13) | 2 024(87.92) | |||
ALT( | 21±16 | 27±20 | 10.371 | <0.001 | 血脂异常〔n(%)〕 | 457.264a | <0.001 | |||
AST( | 23±11 | 25±12 | 5.240 | <0.001 | 无 | 1 687(71.79) | 1 183(51.39) | |||
ALT/AST | 0.88±0.32 | 1.04±0.37 | 15.191 | <0.001 | 高胆固醇血症 | 285(12.13) | 128(5.56) | |||
GGT〔M(QR),U/L〕 | 20.17(31.60) | 24.47(41.19) | 56.332b | <0.001 | 高三酰甘油血症 | 256(10.89) | 618(26.85) | |||
eGFR〔 | 88.35±13.13 | 84.84±15.02 | 8.494 | <0.001 | 混合性高脂血症 | 90(3.83) | 147(6.39) | |||
白细胞计数( | 5.5±1.1 | 6.9±1.5 | 35.590 | <0.001 | 低高密度脂蛋白血症 | 32(1.36) | 226(9.81) | |||
中性粒细胞计数( | 3.2±0.9 | 4.0±1.2 | 25.921 | <0.001 | 分组〔n(%)〕 | 341.805a | <0.001 | |||
单核细胞计数( | 0.3±0.1 | 0.5±0.1 | 55.544 | <0.001 | 对照组 | 1 181(50.26) | 767(33.32) | |||
淋巴细胞计数( | 1.9±0.6 | 2.2±0.7 | 19.815 | <0.001 | NAFLD组 | 725(30.85) | 523(22.72) | |||
血小板计数( | 223.2±59.4 | 237.3±64.9 | 7.740 | <0.001 | MAFLD组 | 444(18.89) | 1 012(43.96) | |||
NLR( | 1.84±0.75 | 1.95±0.99 | 20.166 | <0.001 |
Table 2 Comparison of general information,anthropometric indicators,blood pressure,biochemical indicators,routine blood test results in physical examinees with target metabolic disorders by monocyte to high-density lipoprotein cholesterol ratio
项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | 项目 | MHR≤0.292(n=2 350) | MHR>0.292(n=2 302) | 检验统计量值 | P值 | |
---|---|---|---|---|---|---|---|---|---|---|
性别(男/女) | 455/1 905 | 1 084/1 218 | 417.727a | <0.001 | PLR( | 126.88±43.84 | 114.00±41.44 | 105.961 | <0.001 | |
年龄( | 63.5±8.2 | 65.1±8.7 | 6.504 | <0.001 | LMR( | 0.18±0.06 | 0.24±0.09 | 657.565 | <0.001 | |
BMI( | 24.8±3.4 | 26.2±3.4 | 14.623 | <0.001 | ANI〔M(QR)〕 | -2.94(0.22) | -2.45(0.97) | 1.351b | 0.245 | |
腰围( | 81.0±8.5 | 86.7±8.7 | 22.600 | <0.001 | LAP( | 35.75±26.48 | 57.86±47.07 | 19.792 | <0.001 | |
臀围( | 92.1±6.2 | 95.1±6.4 | 253.068 | <0.001 | AIP( | -0.03±0.27 | 0.22±0.29 | 30.217 | <0.001 | |
腰臀比( | 0.88±0.06 | 0.91±0.06 | 20.016 | <0.001 | 腰围分类〔n(%)〕 | 169.495 | <0.001 | |||
收缩压( | 141±17 | 140±18 | 1.837 | 0.066 | ≥90 cm(男)或≥85 cm(女) | 668(28.43) | 1 080(46.92) | |||
舒张压( | 86±9 | 86±10 | 1.152 | 0.249 | <90 cm(男)或<85 cm(女) | 1 682(71.57) | 1 222(53.08) | |||
空腹血糖( | 6.2±1.7 | 6.7±2.2 | 9.522 | <0.001 | BMI分类 | 161.870a | <0.001 | |||
总胆固醇( | 5.22±1.05 | 4.94±1.09 | 8.854 | <0.001 | 正常 | 913(38.85) | 563(24.46) | |||
三酰甘油( | 1.58±0.87 | 2.24±1.63 | 17.348 | <0.001 | 超重 | 961(40.89) | 1 048(45.53) | |||
LDL-C( | 3.39±0.99 | 3.18±0.97 | 7.223 | <0.001 | 肥胖 | 476(20.26) | 691(30.01) | |||
HDL-C( | 1.53±0.34 | 1.18±0.25 | 40.574 | <0.001 | 高血压 | 5.788a | <0.001 | |||
总胆红素( | 12.16±5.22 | 12.24±5.01 | 0.234 | 0.629 | 无 | 232(9.87) | 278(12.08) | |||
血尿酸( | 304.45±73.32 | 351.25±85.38 | 20.072 | <0.001 | 有 | 2 118(90.13) | 2 024(87.92) | |||
ALT( | 21±16 | 27±20 | 10.371 | <0.001 | 血脂异常〔n(%)〕 | 457.264a | <0.001 | |||
AST( | 23±11 | 25±12 | 5.240 | <0.001 | 无 | 1 687(71.79) | 1 183(51.39) | |||
ALT/AST | 0.88±0.32 | 1.04±0.37 | 15.191 | <0.001 | 高胆固醇血症 | 285(12.13) | 128(5.56) | |||
GGT〔M(QR),U/L〕 | 20.17(31.60) | 24.47(41.19) | 56.332b | <0.001 | 高三酰甘油血症 | 256(10.89) | 618(26.85) | |||
eGFR〔 | 88.35±13.13 | 84.84±15.02 | 8.494 | <0.001 | 混合性高脂血症 | 90(3.83) | 147(6.39) | |||
白细胞计数( | 5.5±1.1 | 6.9±1.5 | 35.590 | <0.001 | 低高密度脂蛋白血症 | 32(1.36) | 226(9.81) | |||
中性粒细胞计数( | 3.2±0.9 | 4.0±1.2 | 25.921 | <0.001 | 分组〔n(%)〕 | 341.805a | <0.001 | |||
单核细胞计数( | 0.3±0.1 | 0.5±0.1 | 55.544 | <0.001 | 对照组 | 1 181(50.26) | 767(33.32) | |||
淋巴细胞计数( | 1.9±0.6 | 2.2±0.7 | 19.815 | <0.001 | NAFLD组 | 725(30.85) | 523(22.72) | |||
血小板计数( | 223.2±59.4 | 237.3±64.9 | 7.740 | <0.001 | MAFLD组 | 444(18.89) | 1 012(43.96) | |||
NLR( | 1.84±0.75 | 1.95±0.99 | 20.166 | <0.001 |
Figure 4 Multivariate regression tree analysis of the association of sex,BMI,triacylglycerol,and fasting blood glucose with monocyte to high-density lipoprotein cholesterol ratio
[1] |
|
[2] |
|
[3] |
|
[4] |
中华人民共和国卫生部疾病控制司. 血吸虫病防治手册[M]. 3版. 上海:上海科学技术出版社,2000.
|
[5] |
李岳生. 血吸虫病诊断与治疗[M]. 北京:人民卫生出版社,2006.
|
[6] |
中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版)[J]. 中华内分泌代谢杂志,2018,34(7):549-554. DOI:10.3760/cma.j.issn.1000-6699.2018.07.004.
|
[7] |
|
[8] |
中华医学会,中华医学会杂志社,中华医学会消化病学分会,等. 酒精性肝病基层诊疗指南(2019年)[J]. 中华全科医师杂志,2020,19(11):990-996. DOI:10.3760/cma.j.cn114798-20200812-00898.
|
[9] | |
[10] |
中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等.中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志,2019,24(1):24-56. DOI:10.3969/j.issn.1007-5410.2019.01.002.
|
[11] |
中华医学会,中华医学会杂志社,中华医学会全科医学分会,等. 血脂异常基层诊疗指南(2019年)[J]. 中华全科医师杂志,2019,18(5):406-416. DOI:10.3760/cma.j.issn.1671-7368.2019.05.003.
|
[12] |
|
[13] |
张玄娥,顾蕾,张晓燕,等. 上海杨浦中老年社区人群内脏脂肪指数和脂质蓄积指数与血尿酸的相关性[J]. 同济大学学报(医学版),2020,41(2):185-191. DOI:10.16118/j.1008-0392.2020.02.008.
|
[14] |
李礼,王凤荣. 冠状动脉Gensini评分、血浆致动脉硬化指数与不稳定型心绞痛中医证型相关性的研究进展[J]. 中国民间疗法,2020,28(24):113-115. DOI:10.19621/j.cnki.11-3555/r.2020.2445.
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
唐任宽. 慢性炎症状态下脂质代谢紊乱及肝脏、主动脉损害的分子机制[D]. 重庆:重庆医科大学,2008.
|
[20] |
顾伟根,冯静亚. 超重和肥胖人群非酒精性脂肪肝的流行现状及相关危险因素分析[J]. 甘肃医药,2015,34(2):112-115.
|
[21] |
赵波,胡来明,李小莉. 血脂及炎症指标在非酒精性脂肪肝合并颈动脉粥样硬化患者中的改变[J]. 胃肠病学和肝病学杂志,2017,26(12):1406-1408. DOI:10.3969/j.issn.1006-5709.2017.12.020.
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||